Rhythm Pharmaceuticals Target Price

See Rhythm Pharmaceuticals's analyst price targets ($140) vs the current share price.

Get informed when a big investor buys or sells

+ Follow

Share Price

$102.44

Average Target Price

$144.86

41.4% upside

7 analysts in the last 4 months

High: $160 | Low: $120

Analyst Recommendations

No recommendations in the last 4 months.

Revenue & Income Forecast

Analysts' Target Prices

Date	Analyst	Price Target	Current Upside/Downside
2026-08-28	Deutsche BankDavid Hoang	$120	17.1% upside
2026-08-05	Canaccord Genuity	$154	50.3% upside
2026-08-05	National Bank	$160	56.2% upside
2026-07-07	RBC Capital	$141	37.6% upside
2026-06-16	Canaccord GenuityWhitney Ijem	$151	47.4% upside
2026-06-15	Stifel NicolausPaul Matteis	$133	29.8% upside
2026-06-15	Wells Fargo	$155	51.3% upside
2026-05-07	Canaccord Genuity	$143	39.6% upside
2026-03-12	Telsey Advisory	$143	39.6% upside
2026-03-12	Wells Fargo	$143	39.6% upside
2026-03-03	JefferiesDennis Ding	$125	22% upside
2026-02-26	Stifel NicolausPaul Matteis	$131	27.9% upside
2026-02-18	RBC CapitalLisa Walter	$145	41.5% upside
2026-01-20	H.C. Wainwright	$125	22% upside
2026-01-20	Wells FargoDerek Archila	$145	41.5% upside
2025-12-22	H.C. WainwrightRaghuram Selvaraju	$123	20.1% upside
2025-12-17	GuggenheimSeamus Fernandez	$140	36.7% upside
2025-12-12	Goldman Sachs	$157	53.3% upside
2025-12-12	Canaccord GenuityWhitney Ijem	$141	37.6% upside
2025-12-11	Morgan Stanley	$150	46.4% upside
2025-10-17	Goldman SachsCorinne Johnson	$139	35.7% upside
2025-10-16	Morgan Stanley	$129	25.9% upside
2025-09-29	H.C. WainwrightRaghuram Selvaraju	$110	7.4% upside
2025-09-25	JMP SecuritiesJonathan Wolleben	$142	38.6% upside
2025-08-05	Morgan Stanley	$109	6.4% upside
2025-07-10	OppenheimerLeland Gershell	$110	7.4% upside
2025-07-10	Goldman SachsCorinne Johnson	$97	5.3% downside
2025-07-09	Morgan StanleyMichael Ulz	$95	7.3% downside
2025-03-05	Stifel Nicolaus	$78	23.9% downside
2025-03-03	H.C. Wainwright	$70	31.7% downside
2025-01-01	JefferiesDennis Ding	$80	21.9% downside
2024-12-05	Goldman SachsCorinne Jenkins	$66	35.6% downside
2024-11-06	NeedhamAlan Carr	$64	37.5% downside
2024-11-06	Goldman SachsCorinne Jenkins	$59	42.4% downside
2024-09-18	H.C. WainwrightRaghuram Selvaraju	$64	37.5% downside
2024-09-17	JMP SecuritiesJonathan Wolleben	$64	37.5% downside
2024-07-25	NeedhamAlan Carr	$55	46.3% downside
2022-11-10	Goldman Sachs	$35	65.8% downside
2022-08-07	Goldman SachsCorinne Jenkins	$28	72.7% downside
2022-07-12	Goldman SachsCorinne Jenkins	$6	94.1% downside
2022-06-17	Needham	$25	75.6% downside
2022-06-17	Stifel NicolausDae Gon Ha	$25	75.6% downside

Rhythm Pharmaceuticals (RYTM) FAQ

Rhythm Pharmaceuticals's target price stands at $140. Stockcircle updates this page with the newest filings so you can track how the metric evolves quarter by quarter.

The Street's average target of $140 for RYTM implies 41.4% upside versus today's price ($102.44). Positive implied upside usually reflects optimism on growth or margins, while a large downside can signal valuation or fundamental concerns. Check recommendation mix and recent target changes for more context.

The history chart shows how Rhythm Pharmaceuticals's target price evolved across reporting periods, while the comparison chart places RYTM next to similar companies. Use both: a rising metric that still lags peers tells a different story than a rising metric that already leads the group. Growth charts, when available, highlight acceleration or slowdown.

Yes — within Healthcare, target price is commonly used to spot outliers. Rhythm Pharmaceuticals's reading of $140 is a starting point; confirm whether differences come from growth, margins, accounting choices, or one-time items before treating an outlier as a buy or sell signal.